



- (51) **International Patent Classification:**
C12Q 1/68 (2006.01)
- (21) **International Application Number:**
PCT/US2013/051824
- (22) **International Filing Date:**
24 July 2013 (24.07.2013)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
61/676,484 27 July 2012 (27.07.2012) US
61/769,271 26 February 2013 (26.02.2013) US
61/829,327 31 May 2013 (31.05.2013) US
- (71) **Applicant (for all designated States except US):** NOVARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).
- (72) **Inventors; and**
- (71) **Applicants (for US only):** CAO, Alexander [US/US]; c/o Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). MORRISSEY, Michael [US/US]; c/o Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). SONKIN, Dmitriy [US/US]; c/o Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). PALMER, Michael [US/US]; c/o Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US).
- (74) **Agent:** CHAPMAN, Jennifer C.; Novartis Pharmaceuticals Corporation, Patent Department, Bldg. 101, One Health Plaza, East Hanover, New Jersey 07936-1080 (US).
- (81) **Designated States (unless otherwise indicated, for every kind of national protection available):** AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) **Designated States (unless otherwise indicated, for every kind of regional protection available):** ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
- Declarations under Rule 4.17:**
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- Published:**
- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) **Title:** PREDICTION OF TREATMENT RESPONSE TO JAK/STAT INHIBITOR

(57) **Abstract:** The invention includes, in part, a method of selecting a subject having cancer for treatment with a JAK/STAT inhibitor or and a method of determining if a therapeutically effective dose of a JAK/STAT inhibitor has been administered.

